There are around 10,300 new bladder cancer cases in the UK every year (1). Our journey began by being one of them.
About ten years ago, one of the founders of Videometrics went through the bladder cancer patient care pathway and being an expert in image analysis, he immediately recognised that this was an area where our skillsets could help.
Therefore, the team here at Biosignatures partnered with the clinical experts at Newcastle Upon Tyne Hospitals (NUTH) and armed with their strengths and experience in urology and our strengths in visual perception, advanced imaging software plus a strong personal motivation, formed the Videometrics concept. An innovative, new medical device which we believe will revolutionise the management of bladder cancer.
With support from Innovate UK, we ran a study called CICERO (CANC 4362) which gained us direct access to the challenges clinicians face, and well as significant data to support our development of the system.
To keep up to date with the latest innovations check back regularly or email to find out more about our clinical studies: firstname.lastname@example.org.
References: 1. Cancer Research UK. Bladder cancer statistics. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bladder-cancer#heading-Zero [Accessed July 2018]
Bringing together clinicians and developers is essential for research and development in health care innovations. We believe that creating a network of ideas, approaches and feedback is an essential part of any new system to guarantee a high level of relevance. This is why our R&D starts in the clinic, talking to the experts. The CICERO study, run in partnership with NUTH and supported by Innovate UK, gained us direct access to the clinicians and highlighted the challenges they face. This ensured important decisions were made accurately in the early stages of Videometrics. In addition, we were able to test the performance of the features and enhancements with real patient data, as we built an archive of cystoscopy examination recordings as part of the project.
This would not have been possible without the support of Innovate UK, the funding allowed us to fund the CICERO study as well as building the project team and successfully developing the system. The support made a huge difference and allowed us to proceed into the development stage accurately and faster than would have otherwise been possible.
Will Dracup, CEO: “The whole process was absolutely key to making sure we were going in the right direction, and I would say the biggest benefit was the interactions with the clinical experts to ensure that the product does what they need.”
Videometrics has a program of ongoing research and development to further optimise the diagnosis of bladder cancer and improve patient care. As part of our ongoing efforts we are collecting clinical data to support our innovations. We are now in the process of putting together a multisite study to gather evidence of the economic benefits for Videometrics, to develop our “cystograph” technology and to collect data for an exciting long term AI project. Check back early summer for further updates, but in the meantime, please do get in touch if you’d like to find out more about Videometrics.
We’d like to thank everyone who attended our poster session lead by Mr Rakesh Heer PhD FRCS(Urol) at EAU 2018 who presented the findings from our observational proof-of-concept study of flexible cystoscopy examination recordings from a symptomatic adult population.
We began our clinical study, CICERO, right at the start of our R&D process. It addressed the safety and effectiveness of the medical device when conducted in a clinical setting, with the patient-device interaction. In addition, we generated the essential data we needed to ensure the system operated efficiently and as intended. CICERO was part of an Innovate UK-funded project to develop a software-based system to record and enhance cystoscopy video.
Listen to our findings below. If you would like to receive a copy of our poster or the report findings, please contact: email@example.com
Session: Poster Session 88 Modelling as applied to imaging and treatment techniques
Location: Monday, 19 March 2018, 15:45 – 17:15, Blue Area, Room 4 (Level 0)
Thank you I’m going to be talking about bladder cancer imaging. So there are limitations to what we can see, what the camera catches. Those limitations are because there are biophysical limitations to the eye and also because there are neurophysiological limitations to image perception. However there’s much more that is captured by the camera and there are some very simple image enhancements that could be made to standard video capture, and you can see in this picture here on the left. We’ve got a picture of the bladder lining and on the right an application of some of these simple enhancements taking into account the particular shortcomings we have with the human eye perception. As part of a study with an industrial collaborator funded by Innovate UK we were able to video film 123 cystoscopies in a haematuria clinic, bladder cancer follow-up cystoscopy clinic. Out of those there were 30+ abnormalities and 13 were referred for biopsy and the histology was noted. We then had a look at the imaging and the effective imaging. We compared students and we compared consultants, before and after enhancement.
The data is summarised right there on the graph what we see is that consultants are actually quite good at doing cystoscopy which is a relief. And the enhancement added very little to that. On the left you see the novices actually do have a shortfall in their ability to detect lesions and when we use the enhancement it does improve with a relative rate at 11% of their performance. So in conclusion what we have here is a video capture mechanism. It allows inexperienced more junior staff to make a referral with that video image capture. If they have the enhancement it helps them make the right call if they’re still uncertain they can ask for a more senior judgement on that.
It’s a stepping stone moving forward to perhaps more significant ambitions. What this imaging allows us to do is to create a 2D picture. So this 3D mapping can be resolved into a 2D picture and we’re generating something that we’re calling a cystograph. It’s very much akin to the idea of a radiograph. We know bladder cancer is incredibly expensive to manage because of its surveillance, most of that cost comes from consultant delivered cystoscopy. If we now have technicians delivering a bladder map using a panoramic type stitching together of an image into a 2D map, a cystograph, a consultant can batch process this in a single session looking at maybe 50+ cases. Moreover the image enhancement forms the basis for algorithms for artificial intelligence and artificial intelligence aided diagnoses and potentially even pre-screening. Very similar to what we see in the histological screening of cervical carcinoma pap smears. Thank you.
In 2018 Biosignatures plans to initiate a multisite study to evaluate the utility and efficiency of the Videometrics system with the cystograph (bladder mapping) technology. As part of the initial planning for this study, we attended a Perspectives In Cancer Research Group meeting. This is a group of volunteers who all have personal experience of cancer, the group objective is to support cancer research at the Freeman Hospital in Newcastle.
The meeting gave us a valuable insight into the patient perspective of the system and the utility of the bladder mapping technology as a tool to assist in the patient pathway and current procedures.
Biosignatures are looking for hospitals to be involved in the study, if you would like to be involved, or have any questions, please contact Sarah Groves our Clinical Operations Manager:
Technical development has already started on the creation of a map of the bladder walls, however, no video has yet provided us with full coverage of the bladder. We hope this study can demonstrate the utility of a systematic review of the whole bladder.